Citi lowered the firm’s price target on Schrodinger to $37 from $39 and keeps a Buy rating on the shares. The company started off the year with softer than expected software and drug discovery revenues, the analyst tells investors in a research note.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter